Search the Newsreel

Vanguard Capital Management (ZVRA) discloses 3.0M-share Zevra Therapeutics position on 13G

Vanguard Capital Management has filed a Schedule 13G, disclosing a passive ownership stake of 3,024,980 shares in Zevra Therapeutics Inc (ZVRA), representing 5.11% of the outstanding common stock. Vanguard holds sole voting power over 386,070 shares and sole dispositive power over all 3,024,980 shares, …

Zevra Therapeutics Inc (ZVRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Zevra Therapeutics Inc (ZVRA), highlighting its current valuation score and P/E ratio within the Pharmaceuticals industry. It notes that the company's valuation score is 7.58, ranking 120 out of 155, and its P/E ratio is 4.57, which …

Zevra Therapeutics (ZVRA) Stock Forum and Discussion

This article provides a platform for discussion and a forum for investors interested in Zevra Therapeutics (ZVRA) stock. It serves as a central point for sharing insights, news, and analysis related to the company's performance and future outlook.

Levi & Korsinsky Announces Investigation of Securities Claims Against Zevra Therapeutics, Inc. (ZVRA)

Levi & Korsinsky has initiated an investigation into Zevra Therapeutics, Inc. (ZVRA) following a significant 24% pre-market stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, Zevra's …

Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zevra Therapeutics, Inc. (ZVRA) after the company received a negative opinion from the European Medicines Agency regarding its drug arimoclomol, leading to a sharp drop in stock price. The firm …

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics

SueWallSt, powered by Levi & Korsinsky LLP, is investigating potential securities claims against Zevra Therapeutics (NASDAQ: ZVRA) following a significant stock drop on July 24, 2026. The decline occurred after the European Medicines Agency's CHMP issued a negative opinion on Zevra's drug arimoclomol for …

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Zevra Therapeutics, Inc. (NASDAQ: ZVRA) for potential securities law violations after Zevra received a negative opinion from the European Medicines Agency regarding its drug arimoclomol (Meplyffa), causing its shares to fall significantly. SBS …

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

Levi & Korsinsky, LLP has launched an investigation into Zevra Therapeutics (ZVRA) after its shares dropped approximately 24% following a negative opinion from European regulators on arimoclomol, their lead product for Niemann-Pick disease type C. The investigation aims to determine if investors who suffered …

Zevra Europe Entry Plans For Neimann-Pick Drug Put On Hold

Zevra Therapeutics has put its plans for entering the European market with its Niemann-Pick disease drug on hold. The article, authored by Kevin Grogan, provides this key update regarding the company's strategy for its rare disease treatment.

H.C. Wainwright reiterates Zevra stock rating on EU setback

H.C. Wainwright has reiterated its Buy rating and $26.00 price target for Zevra Therapeutics (NASDAQ:ZVRA) despite a regulatory setback in Europe for MIPLYFFA. The firm believes the issues are related to statistical analysis rather than new concerns, and Zevra plans to seek re-examination of …

Zevra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ZVRA

Zevra To Appeal EMA's Negative Opinion On Arimoclomol For Niemann-Pick Disease Type C

Zevra Therapeutics announced that the European Medicines Agency (EMA) has issued a negative opinion on its Marketing Authorization Application for Arimoclomol, a treatment for Niemann-Pick disease type C. The company plans to appeal this decision, asserting confidence in the drug's potential based on existing …

Zevra Therapeutics Down Over 24%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk

Zevra Therapeutics is experiencing a significant stock decline, down over 24%. This places the company on track for its largest single-day percentage decrease since March 2021, according to Data Talk. The article content is empty, so no further details are available regarding the cause …

Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C

Zevra Therapeutics' stock (ZVRA) dropped following a negative opinion from the European Medicines Agency's CHMP regarding its drug arimoclomol for Niemann-Pick disease type C. The company plans to request a re-examination while continuing to provide patient access through an Expanded Access Program. Despite the …

Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application

Zevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). The company plans to request a re-examination of this …

Daybu readthrough in EU? Zevra’s NPC bid flounders

Zevra Therapeutics plans to ask the EMA's CHMP to reconsider its decision regarding arimoclomol for Niemann-Pick disease type C (NPC). This move follows the CHMP's initial ruling that the efficacy for NPC had not been sufficiently proven. Zevra aims to emulate Acadia Pharmaceuticals' success …

ZVRA Stock Slides As Traders Gauge Pullback And Cash Strength

Zevra Therapeutics Inc. (ZVRA) has experienced a significant stock slide, falling over 22% from the mid-$14s to the high-$9s, breaking previous support levels. Despite this sharp pullback, the company maintains a strong financial position with minimal debt and over $95M in cash, although much …

Zevra down on EU snub for rare disease therapy (ZVRA:NASDAQ)

Zevra Therapeutics (ZVRA) shares dropped approximately 30% in premarket trading after an expert panel of the EU drug regulator declined to endorse its lead product, arimoclomol, for Niemann-Pick disease type C. This rare neurodegenerative condition is the target for the therapy, which failed to …

Zevra Therapeutics to Seek Re-Examination After Negative CHMP Opinion on Arimoclomol for NPC

Zevra Therapeutics announced that the European Medicines Agency's CHMP issued a negative opinion regarding its Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). Despite this setback, Zevra plans to request a re-examination, reaffirming its commitment to bringing the drug …

After Negative EU Opinion, Zevra Supports Access for Eligible Patients

Zevra Therapeutics received a negative opinion from the European Medicines Agency’s CHMP regarding its Marketing Authorization Application for arimoclomol to treat Niemann-Pick disease type C (NPC) in the EU. Despite this setback, the company plans to request a re-examination and continues to provide arimoclomol …

Zevra Therapeutics Provides Update on Regulatory Submission

Zevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on their Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). Despite this setback, the company plans to request a …

ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

ZeVra Therapeutics jumps 29% as Miplyffa patent gains FDA exclusivity through 2041

ZeVra Therapeutics shares rose 29% after its drug Miplyffa received FDA patent exclusivity until 2041 for Niemann-Pick Disease Type C. The company reported strong financial results for FY25, including profitability, debt retirement, and significant cash reserves. With an innovative pipeline and attractive valuation, ZeVra …

Zevra’s Aug. 5 results webcast will be replayed for 90 days

Zevra Therapeutics (NasdaqGS: ZVRA) announced it will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. A replay of the webcast will be available for …

Zevra Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call

Zevra Therapeutics announced it will release its second quarter 2026 corporate and financial results on August 5, 2026, followed by a conference call and audio webcast at 4:30 p.m. ET. The company, which focuses on developing therapies for rare diseases, highlighted its commitment to …

ZVRA - Zevra Therapeutics: Galloping Through a Green Safari

Zevra Therapeutics has successfully transitioned from a prodrug company to a rare disease powerhouse, marked by the FDA approval of MIPLYFFA for Niemann-Pick disease Type C and a $100 million sale of a Rare Pediatric Disease Priority Review Voucher. The company's financial standing is …